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There is a growing body of evidence to support a role for oxidative stress in Alzheimer's disease (AD), with increased levels of lipid
peroxidation, DNA and protein oxidation products (HNE, 8-HO-guanidine and protein carbonyls respectively) in AD brains. The brain is a highly
oxidative organ consuming 20% of the body's oxygen despite accounting for only 2% of the total body weight. With normal ageing the brain
accumulates metals ions such iron (Fe), zinc (Zn) and copper (Cu). Consequently the brain is abundant in antioxidants to control and prevent the
detrimental formation of reactive oxygen species (ROS) generated via Fenton chemistry involving redox active metal ion reduction and activation
of molecular oxygen. In AD there is an over accumulation of the Amyloid β peptide (Aβ), this is the result of either an elevated generation from
amyloid precursor protein (APP) or inefficient clearance of Aβ from the brain. Aβ can efficiently generate reactive oxygen species in the presence
of the transition metals copper and iron in vitro. Under oxidative conditions Aβ will form stable dityrosine cross-linked dimers which are
generated from free radical attack on the tyrosine residue at position 10. There are elevated levels of urea and SDS resistant stable linked Aβ
oligomers as well as dityrosine cross-linked peptides and proteins in AD brain. Since soluble Aβ levels correlate best with the degree of
degeneration [C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, C.L. Masters, Soluble pool of Abeta
amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease, Ann. Neurol. 46 (1999) 860–866] we suggest that the toxic Aβ
species corresponds to a soluble dityrosine cross-linked oligomer. Current therapeutic strategies using metal chelators such as clioquinol and
desferrioxamine have had some success in altering the progression of AD symptoms. Similarly, natural antioxidants curcumin and ginkgo extract
have modest but positive effects in slowing AD development. Therefore, drugs that target the oxidative pathways in AD could have genuine
therapeutic efficacy.
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The Aβ peptide was first purified and sequenced from
amyloid plaques found in AD and Down's syndrome brain [2,3].
It is typically a 39–42 residue polypeptide derived from the
proteolytic processing of the APP molecule and consists of a
largely hydrophillic N-terminal domain (1–28) and a C-terminal
hydrophobic domain (29–39/43) derived from the APP
transmembrane domain (Fig. 1). APP can be processed via
two proteolytic pathways, each resulting in distinct cleavage
products. Cleavage of APP by β-secretase generates a
membrane bound C-terminal fragment which is the substrate
for γ-secretase, which cleaves within the transmembrane
domain of the C-terminal APP fragment to generate full length
Aβ (Fig. 1). The alternative pathway involves initial cleavage of
APP by α-secretase, followed by γ-secretase resulting in the
truncated P3 fragment (Fig. 1).
APP is a ubiquitously expressed type 1 transmembrane
protein and is a member of a multigene family which includes
amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2)
[4–8]. The biological function of the APP family remains
unknown. APP exhibits a variety of potential biological
functions including regulation of intracellular calcium [9,10],
cell growth [11–13], cell adhesion [14–17], axonal transport
of vesicles [18] and metal ion homeostasis [19–21]. APP
contains a metal binding domain in the N-terminal cysteine-Fig. 1. Amyloid beta peptide (Aβ), a 39–43 amino acid transmembrane peptide is ge
initiates the non-amyloidogenic processing pathway of APP. APP in a multi-domain
(metal), acidic, Kunitz-type serine protease inhibitor (KPI), OX-2 homology sequ
domains [217]. The cleavage sites of the secretases are indicated by the arrows above
the familial mutations of Aβ are indicated below the sequence.rich region adjacent to the growth factor-like domain [11,19–
21]. Structural studies indicate the metal binding domain
possesses structural similarities to known copper chaperones
such as the Menkes copper-transporting ATPase fragment,
metallochaperone Atx1, and SOD1 copper chaperone [21].
The APP copper binding domain exhibits a strong affinity for
Cu2+ ions (Kd≈10 nM) and can reduce Cu2+ ions in vitro
[19,20,22]. APP and APLP2 knockout mice have elevated Cu
levels in the brain cortex and liver [23] while APP
overexpressing mice exhibit a reduction in metals including
copper ions [24–26].
2. Oxidative stress in AD
The brain is the most aerobically active organ in the body
due its high metabolic requirements. The brain accounts for 2%
of total body mass yet consumes 20% of total oxygen in a
resting individual. Therefore it is imperative to maintain
oxidative balance and control in the brain, and this is tightly
regulated by antioxidants that are present in vastly higher
amounts than in any other organ. Therefore modifications in
normal oxidative metabolism as observed in AD brain provide
strong evidence that oxidative stress plays an important role in
AD pathogenesis (Fig. 2).
As a general principle, the chemical origin of the majority
of ROS is the reaction of molecular oxygen with the redoxnerated from APP cleavage by β- and γ-secretase. α-secretase cleavage of APP
protein consisting of eight domains: heparin binding (heparin), metal binding
ence (OX-2), carbohydrate, transmembrane (TM) and the cytoplasmic (cyto)
the Aβ sequence. The transmembrane domain of Aβ is highlighted in orange and
Fig. 2. Aβ reduction of Cu2+ ions generates Aβ radicals (Aβ▪) that extract
protons from surrounding lipids and proteins generating hydroxy-2-nonenal
(HNE) and carbonyls respectively. Cu+ reacts with molecular oxygen (O2)
eventuating in H2O2 formation.
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to occupy multiple valence states and undertake facile redox
cycling, thereby activating molecular oxygen, has been
utilized by a variety of enzymes including ceruloplasmin
[28], cytochrome c oxidase [28] and amine oxidases [29].
However, unregulated redox-active metals will inappropriately
react with oxygen to generate ROS. Moreover, there is
increased glucose-6-phosphate dehydrogenase activity [30,31],
increased heme oxygenase levels in diseased brain [32] and
the presence of oxygen radical-mediated chemical attack
resulting in increased free carbonyls, lipid peroxidation
adducts, protein nitration and mitochondrial and nuclear
DNA oxidation adducts.
A broad range of lipid peroxidation products can evolve
from the cascade of events described above. High levels of
chemically reactive electrophillic aldehydes malondialdehyde
and free 4-hydroxy-2-nonenal (HNE) have been found in AD
brain tissue [33–35]. These aldehydes readily react with cellular
nucleophiles such as DNA, proteins and other lipids and
elevated HNE-protein adducts have been detected in human AD
brain [34,36,37]. They are potentially more perilous than free
radicals because of their longer half-lives which allow them to
diffuse away from their site of formation [38]. Polyunsaturated
fatty acids, such as arachidonic acid and docosohexanoic acid,
found in high abundance in brain [39] are highly oxidisable and
hence vulnerable constituents of membrane phospholipids.
Taken together, the above studies suggest that in an AD brain
free radicals could induce lipid peroxidation leading to highly
reactive aldehydes that initiate a cascade of oxidation events
resulting in cellular dysfunction and ultimately death. There is
significant evidence to indicate that Aβ can generate these free
radicals (see later section).
Protein carbonyls are a major marker of protein oxidation
and can be generated from direct free radical attack on amino
acid side chains, glycation, glycoxidation or from lipid
oxidation products as discussed above. Elevated levels of
protein carbonyl exist in the frontal pole, hippocampus and
superior middle temporal gyrus of AD patients and correlate
well with AD histopathology [40–45]. Nitrotyrosine and
dityrosine cross-linked protein are elevated 8-fold and 3-fold
respectively in hippocampus and neocortical regions of AD
brain compared to age matched controls [26,46,47]. Both ofthese oxidation products in mammals generally correlate with
oxidative stress [48–50]. Furthermore, neuritic and cored
amyloid plaques show evidence of oxidatively modified
Aβ [51] with much of the Aβ isolated from plaque containing
methionine sulfoxide [52].
Further evidence of oxidative stress in AD is the modifica-
tion of antioxidant activity in the brain. Thioredoxin is an
antioxidant protein which is decreased in AD amygdala and
hippocampus/parahippocampal gyrus. In contrast, the thiore-
doxin protein reductase shows increased activity in the
amygdala and cerebellum of AD patients [53]. The antioxidant
enzyme glutathione transferase, which is primarily responsible
for HNE clearance, is decreased in several regions in AD brain
including the hippocampus [54]. Furthermore, conjugated
glutathione and HNE are elevated in the substantia innominata
and the hippocampus in severe AD cases [55]. These two
regions of the brain are known to be preferentially affected by
the disease. HNE conjugation to glutathione by glutathione
transferase is a cellular mechanism to inactivate toxic HNE.
Therefore, increased levels would indicate an elevated cellular
defence against lipid peroxidation.
The antioxidant enzyme superoxidase dimutase (SOD)
displays elevated expression levels in AD brains compared to
age matched controls [56]. It is also elevated in red blood cells
and lymphoblasts [57–60] which suggests that the normal
compensatory mechanisms against free radical damage may be
insufficient in AD patients. Apolipoprotein allele ε4 increases
the risk of developing AD and it has been shown that AD
patients homozygous for this allele have an increase in brain
catalase activity [61] suggesting a genetic predisposition for
increased ROS generation in some AD suffers. Furthermore, the
administration of the antioxidant vitamins ascorbic acid
(vitamin C) and α-tocopherol (vitamin E) in tandem caused a
decrease in the risk of AD in elderly subjects [62]. Taken
together these observations suggest that prophylactic intake of
antioxidants may be beneficial for those with a genetic risk of
AD.
3. Metals in AD
The brain tightly regulates metal ion homeostasis as a part of
normal physiological processes that play an important role in
neural activity. Various lines of evidence have implicated metal
ions, in particular Cu, Zn and Fe in the pathogenesis of AD
(reviewed in [63]).
Transition metal ions Cu and Zn co-purify with Aβ extracted
from AD plaques [64]. Cu ions are normally bound to Cu
enzymes or proteins like cytochrome c oxidase, ceruloplasmin
and superoxidase dismutase during normal physiological
circulation and are released into the synapse upon presynaptic
excitation reaching up 15 μM in the synaptic cleft [65].
Although found in high concentrations in amyloid plaques
(∼400 μM) [66] compared to the normal brain extracellular
concentration of 0.2–1.7 μM [67–72], most studies of bulk
tissue have found either no statistical difference [73,74] or a
decrease [75,76] in total Cu concentration in AD brain
compared to age matched controls.
Fig. 3. Model of Cu2+ coordination with Aβ in a 3N1O coordination sphere via
His6, His13, His14through the imidazole nitrogens. The fourth oxygen donor
ligand putatively is the hydroxyl of Tyr10, side chain carboxylate or a backbone
carbonyl.
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plaques [66]. Interestingly, only mature cored senile plaques,
not diffuse plaques, showed histochemical reactivity for Zn
[77]. Using inductively coupled plasma mass spectrometry
(ICP-MS), increased Zn levels were detected in cerebrospinal
fluid (CSF) of AD patients [78]. There is conflicting data on
brain Zn in AD levels with one report of bulk brain analysis
indicating decreased levels of Zn in post mortem AD
hippocampus [79], while a separate study observed an increase
in the same region as well as in the amygdala and inferior
parietal lobule [76,80]. Histological staining of normal brain
indicates the distribution of Zn resembles the areas of the brain
most prone to amyloid deposition and neuropathy in AD
which includes the aforementioned hippocampus, amygdala
and parietal lobe [81]. The primary source of labile Zn in the
brain is from Zn released into the synapse during transmission
[82] at ∼200–300 μM [83,84]. Zn ions can promote Aβ
aggregation and plaque formation, and this activity may not be
as a neurotoxic modulator but rather as a neuroprotective agent
since Zn can attenuate Aβ toxicity in cortical cultures [85–89].
The precise mechanism of cytoprotection is not clear, though
possible mechanisms include inherent blockading of mem-
brane channels formed [90–96], Zn enhancement of Na+/K+-
ATPase [86] or competing with Cu for Aβ binding and
thereby inhibiting Aβ initiated redox chemistry [85,97,98].
Oral Zn supplements significantly delay cognitive decline in
AD patients [99–101].
The third transition metal found localized in human amyloid
plaques is Fe. Bulk analysis of post mortem AD brain indicates
that Fe is predominantly localized in neocortical grey matter
[102], amygdala [103] and olfactory tract [73]. Despite having a
high concentration in AD plaques (∼1 μM) [66], Fe ions are not
likely to interact directly with Aβ in vivo. Although in vitro
studies indicate that Fe is able to interact with Aβ [104–106],
unlike the other two transition metals Fe does not co-purify with
Aβ extracted from plaque[64] and is predominantly located in
neuritic processes within the plaque itself associated with
ferritin [107]. A number of studies suggest that Fe homeostasis
is altered in AD [66,107–111], however this is likely to be a
secondary effect via another process such as increased heme
oxygenase activity in response to cellular oxidative stress [32]
or a decrease in functional heme from Aβ binding to heme
increasing free Fe levels [112].
APP knockout mice have an increase in brain Cu levels [23].
In contrast, the Tg2576 APP transgenic mouse model which
overexpresses the human APP Swedish mutation and forms
amyloid plaques [113], display significantly reduced brain Cu
levels prior to the appearance of amyloid neuropathology [24].
Two other APP transgenic mouse models, the APP23 and
TgCRND8 mice also had reduced Cu levels. Zn [77] and Fe
[114] levels were also dysregulated in the Tg2576 mice with the
Tg2576 plaques containing high levels of both ions. The
formation of amyloid plaques is associated with Zn-mediated
Aβ aggregation since crossing the Tg2576 mice with mice
where the synaptic Zinc transport 3 protein was knocked out
reduced the cerebral amyloid burden by 50% compared to
Tg2576 control mice [115].Oxidative stress markers have been detected in 12 month old
senescence accelerated prone (SAMP8) mice which accumulate
brain Aβ and display learning and memory impairments, and
have elevated levels of oxidative stress markers compared to 4
month old mice [116]. Treating the aged SAMP8 mice with
antisense oligonucleotide targeted to the Aβ sequence in APP
showed decreased levels of oxidative stress markers including
protein carbonyls, 3-nitrotyrosine adducts and HNE in the brain
[117]. These results support a link between Aβ and oxidative
stress.
4. Aβ is a metalloprotein
Multivalent metal ions are fundamental to redox chemistry
as they facilitate electron transfers during the redox process.
Aβ is a metalloprotein that displays high affinity binding of
Cu2+, Zn2+ and Fe3+ ions [118]. The metal binding site was
initially mapped to the region between positions 6 and 28.
Solution state NMR implicated three histidine residues (His6,
His13 and His14) in binding Cu
2+. This is supported by EPR
data which suggests a square planar configuration in a 3N1O
co-ordination sphere [119]. The nitrogen atoms involved in
this co-ordination are from the imidazole rings of the three
histidines (Fig. 3). The identity of the oxygen is unclear and it
may be the hydroxyl from Tyr10. Other options include the
oxygen atoms of the sidechain carboxylate of Glu5 [120], N-
terminal aspartate [120], the amino terminus itself [120,121]
or possibly a water molecule [122].
Aβ possesses a strong positive formal reduction potential
and rapidly reduces Cu2+ and Fe3+ to Cu+ and Fe2+,
respectively [98]. Molecular oxygen is then trapped generating
free radical and peroxide species via Fenton chemistry with the
Aβ42 species exhibiting the greatest activity [98] (Fig. 2). The
chemistry of these reactions is discussed in more detail later in
this review. The free radicals generated are suggested to be
involved in the oxidation of the methionine 35 residue (Met35)
[123–129]. The replacement of Met35 with norleucine (sulphur
of methionine is replaced with a methylene group) abolishes the
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wildtype peptide [130]. The free radicals could possibly initiate
the oxidation of the sulfhydryl to a sulfuranyl radical cation,
which can then abstract protons from other lipids (causing lipid
peroxidation) or proteins (initiating protein oxidation).
5. Aβ, metals and redox chemistry
There is good evidence that metal ions mediate the oxidative
stress mechanism of Aβ toxicity. Metal ions modulate Aβ
toxicity in neuronal cultures, with Cu2+ ions increasing Aβ
toxicity whilst Zn2+ ions attenuate it [85]. Likewise, Aβ
dissolved in Fe3+ containing media is toxic to neurons whilst
Aβ in Fe3+ free media is not toxic [131]. The difference in the
activity of the metal ions was attributed to the redox capabilities
of Cu2+ and Fe3+. Aβ/Cu(Fe) complexes are capable of
generating reactive oxygen species such as H2O2 which
mediates toxicity [98,132]. Synthetic Aβ incubated in the
presence of the chelator desferrioxamine (Fe3+ chelator)
exhibited decreased toxicity which was restored by the addition
of 0.1 mM Fe3+ [104]. Synthetic Aβ contains significant
concentrations of Cu and Fe both of which can mediate Aβ
production of H2O2 [133]. The addition of the H2O2 scavenging
enzyme catalase to the cell cultures inhibits Aβ toxicity and
suggests that Aβ neurotoxicity is mediated by ROS generation
[98,132,134–137]. A caveat is that catalase can bind to Aβ and
thus exert a static effect independent of the H2O2 production
[138]. Co-incubation of Aβ with metal chelators can also
attenuates Aβ toxicity [134,139] (Fig. 4).
The production of H2O2 by Aβ is dependant on the presence
of specific redox active metal ions [132,140]. The generated
peroxide may degrade forming a highly reactive hydroxyl
radical (ROS) via Fenton chemistry or a Haber–Weiss reaction
outlined as outlined below [141,142].
Ab þ Mðnþ1ÞþYAb þ Mnþ ðreduction of the metal ionÞ
Mnþ þ O2YMnþ1 þ O 2
O þ2 O

2 þ 2HYH2O2 þ O2 ðproduction of H2O2Þ
Mnþ þ H2O2YMðnþ1Þþ þ OH: þ OH ðFenton ChemistryÞ
O 2 þ H2O2Y; OH:þ OHþ O2 ðHaberWeiss reactionÞ
Aβ generation of ROS requires reduction of metal ions (Cu
or Fe) thus inducing oxidation of another moiety. Mass
spectrometry has shown that Cu2+ ions are able to oxygenate
Aβ with the most likely candidate being the sulphur atom of
methionine 35 (Met35) [143,144]. It has been proposed thatFig. 4. Oxidation of methionine residue leads to the formation of methionine
sulfoxide.Met35 serves as a source of electrons for the reduction of
molecular oxygen to hydrogen peroxide [119,127,130,145–
148] (Eqs. (1)–(5)).
AbMetðSÞ þ Cu2þYAbMetðSþÞ þ Cuþ ð1Þ
AbMetðSþÞ þ CHYAbMetðS2þÞ þ :CH ð2Þ
Cuþ þ O2YCu2þ þ O:2 ð3Þ
AbMetðS2þÞ þ H2OYAbMetðS ¼ OÞ þ 2Hþ ð4Þ
O:2 þ O:2 þ 2HþYH2O2 ð5Þ
consistent with the in vitro data, oxidised methionine Aβ
(AβMet-ox) has been isolated from AD brain amyloid deposits
[149,150] and furthermore is bound to Cu [52].
The redox properties of Aβ indicate it could function as both
an antioxidant and a pro-oxidant under specific conditions. Aβ
has been observed at low concentration (nM range) to have a
neuroprotective and neurotrophic effect on neonatal cell
cultures [151–156]. However, the condition(s) under which
Aβ ceases to act as an anti-oxidant and function as a pro-
oxidant are not clearly understood, although several lines of
evidence indicate the activity is dependant on the concentration
of the peptide. The concentrations of Aβ required to induce
toxicity in vitro is in the micromolar range [89,134,139,157–
162]. In cerebrospinal fluid where Aβ has been reported to act
as an anti-oxidant, the concentration of the peptide is between
0.1 and 1 nM, while at higher concentrations this activity was
ablated [163]. Similarly, anti-apoptotic activity was only
observed at nanomolar levels and conversely at higher
concentrations it was toxic [164]. There is a strong negative
correlation between oxidative damage and Aβ deposition in AD
brain [1,165]. The accumulation of Aβ is either from excessive
production of Aβ or alternatively an impairment of Aβ
clearance pathways. Zn displacement of Cu binding to Aβ
could be a detoxification mechanism followed by deposition
into plaques which may not be toxic. Neuronal cells exposed to
Aβ42 in the presence of both Cu and Zn had lower toxicity than
Aβ plus Cu, suggesting Zn suppressed the Cu-dependent
formation of H2O2 and rescued the cells [85]. Therefore,
localized excessive levels of Aβ and Cu may generate ROS
concentrations exceeding the capacity of the normal oxidation
defence system. Moreover, synaptosomes treated with Aβ
results in the release of free fatty acids and this effect was
inhibited by the antioxidant vitamin E [166].
5.1. The role of methionine 35 in Aβ toxicity
There is conflicting data regarding the role of Met35 in Aβ
neurotoxicity. Met35 is located in the C-terminal portion of the
Aβ peptide, within the putative transmembrane domain and is
the most susceptible side chain to oxidation [167,168].
Investigation into the role of Met35 in Aβ toxicity suggests
the methionine is paramount to the redox chemistry of the
peptide [127]. The sulfur containing methionine could
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initiate a redox chemistry cycle as discussed previously.
An amino acid substitution of Met35 to valine increases Aβ
toxicity compared to the WT peptide [139] whilst nor-
isoleucine or cysteine amino acid substitution ablated it [169].
The oxidised methionine Aβ peptide (AβMet-ox) displayed no
toxicity after a 24 h exposure [130], however longer incubations
of AβMet-ox exerted similar toxicity to wildtype Aβ [134].
These results support the concept that Aβ mediated generation
of ROS is initiated by the Met35 residue. In order for Met35 to
facilitate ROS generation by reducing metal ions, Met35 must
come within ∼19 Å distance of the acceptor atoms for the
electron transfer to occur [170]. This might be achieved by
either the folding of the N and C-terminal ends or via the
fibrillization of the peptide resulting in the metal bound N-
terminal end of one Aβ being stacked adjacent to the Met35 in
the C-terminal end of another Aβ. Under these conditions, Cu2+
induced radicalization of Met35 could also induce the generation
of a stable carbon centred radical on the peptide backbone (most
likely glycine residues), which can subsequently participate in
lipid peroxidation reactions [171]. This is consistent with
elevated post mortem 4-hydroxynonenal (HNE) levels in AD
brain [33,172].
An alternative mechanism to the aforementioned process for
the generation of HNE is based on full length Aβ inserting into
the lipid membrane via its hydrophobic C-terminus wherein the
sulfuranyl radical abstracts a proton from an unsaturated bond in
the membrane phospholipid generating a carbon centred radical
on the lipid. The carbon centred radical can readily react with
molecular oxygen (O·) forming a peroxyl free radical (HO·)
which in turn initiates a cascade of events that amplify the
original Aβ peptide free radical. The lipid peroxidation
products, such as HNE, arise from the systematic breakdown
of the lipids subsequent to the free radical attack [127,173,174].
The oxidation state of the peptide can also affect aggregation
as synthetic AβMet-ox has a slower rate of fibrillization,
presumably by disrupting the switch from small soluble
oligomers to larger insoluble oligomers. By arresting the
oligomerisation to dimers, Aβ is able to be cleared from the
brain before any toxic effect is exerted [175]. Interestingly,
AβMet-ox is more soluble than wildtype Aβ and was unable toFig. 5. A simplified model of the redox chemistry events of Aβ catalytic producinsert into membranes and cause pore formation. However, the
AβMet-ox was still neurotoxic [134] indicating membrane
insertion is not a pre-requisite for Aβ toxicity.
5.2. A model for Aβ redox chemistry
The origin of the electron(s) that cause a reduction in the
oxidation state of the metal ion could be the peptide itself, from
Met35 or from biological reducing agents such as dopamine and
ascorbate [64]. The presence of an external reductant would
permit the catalytic cycling of Cu or Fe without any net
oxidation of the peptide. We used density function theory (DFT)
to propose a detailed reaction scheme of the catalytic cycle that
generates H2O2 (Fig. 5) [135]. The model proposed that as a
consequence of the formation of a reactive tyrosyl radical on
Tyr10, that dityrosine cross-linked Aβ would be generated
giving rise to covalently linked soluble oligomers. The
formation of tyrosyl radicals is known to induce lipid
peroxidation, a feature well characterized in AD.
The DFT model was supported by experimental data for the
catalytic production of H2O2 by Aβ/Cu
2+ and was shown to
resemble the catalytic activity of galactose oxidase (GO). The
role of the tyrosine residue was tested by using Aβ with alanine
substituted for Tyr10 (AβY10A) [135]. The AβY10A readily
formed oligomers but was not toxic to cortical cultures whereas
the wildtype peptide containing dityrosine linked oligomers was
neurotoxic. Moreover AβY10A can catalytically produce H2O2
at half the rate observed for the WT peptide consistent the
pivotal role of the tyrosine residue in the redox chemistry as
predicted by the model [135].
Opazo and colleagues have addressed other aspects of the
model experimentally, specifically the ability of biologically
significant reductants to initiate the redox chemistry [64].
Aβ42, coordinated with up to two equivalents of Cu2+, can
generate H2O2 catalytically by utilizing biological reducing
agents as substrates under conditions where the Cu2+ or
reductant will not form H2O2 themselves. The redox activity
observed was inhibited by the presence of anti-Aβ antibody,
Zn2+ or chelators targeting Cu [64]. Moreover, the toxicity of
Aβ to neuronal cell cultures was accentuated with the addition
of one such reductant dopamine [64].tion of H2O2 with dityrosine Aβ generated as a side product to the reaction.
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In addition to Aβ methionine sulfoxide, a number of other
adducts resulting from redox reactions can be generated.
Synthetically oxidatively modified Aβ products include
tyrosine modified with adducts such as DOPA, dopamine,
dopamine quinine, dihydroxyindol and isodityrosine (shown in
Fig. 6) [176]. Aβ extracted from AD plaques contains
oxidative modifications such as oxidised Met35 [51,149],
modification of the histidines to 2-oxo-histidine [177] and
oxidatively modified tyrosine adducts including 3,4-dihydrox-
yphenylalanine (DOPA), dopamine and dopamine quinine
[46,177,178]. Tyrosine is particularly susceptible to free
radical attack due the conjugated aromatic ring. Evidence of
other dityrosine linked peptides/proteins and 3-nitrotyrosine
(Fig. 6) within the neuronal lesions in AD brain has been
reported [51]. In vitro Aβ42 in the presence of Cu2+ and H2O2
forms dityrosine cross-linked oligomers [179]. In a separate
study, the formation of dityrosine linkage in Aβ facilitated
further peptide aggregation, leading to the formation of higher
order oligomers [143].
The formation of dityrosine adducts in vivo is a generalized
sign of oxidative stress and is a result of free radical reactions
[180,181]. The formation of dityrosine arises from the reaction
of two tyrosine residues, which form carbon centered radicals in
the aromatic ring (Fig. 7). The formation of dityrosine results in
the creation of a very stable, irreversible covalent bond [182].
Stable Aβ oligomers resistant to SDS, urea and formic acid
treatment have been extracted from AD brain tissue [3,183,184]
suggesting that the Aβ peptides are covalently linked.
Furthermore, naturally occurring stable Aβ oligomers but not
monomers or fibrils inhibit hippocampal LTP [185]. We
hypothesize that the Aβ toxic species requires the oxidative
modification of Aβ resulting from redox chemistry that leads toFig. 6. Tyrosine adducts formedthe formation of covalently linked (dityrosine crosslinked)
soluble Aβ oligomers.
6. Therapeutic inventions
6.1. Antioxidants
The use of antioxidants has proven to be a promising
approach for slowing progression of AD by inhibiting oxidative
stress damage linked to cognitive and functional decline. A large
amount of literature exits in relation to the potential benefits of
vitamin supplements as AD prophylactics. Extensive in vitro
studies are being conducted and some appear promising,
however tandem administration of α-tocopherol (Vitamin E)
(Fig. 8a) and ascorbic acid (Vitamin C) (Fig. 8b) only had
modest benefits in elderly subjects [62]. Gossypin (3,3′,4′,5,7,8-
hexahydroxyflavone 8-glucoside) (Fig. 8c), a bioflavonoid from
the yellow petals of hibiscus flowers, is a radical scavenger and
can protect cortical cell cultures [186] from Aβ induced toxicity.
Melatonin (Fig. 8d) is neuroprotective against Aβ toxicity in
vitro [187] and displayed beneficial effects in experimental
mouse models of AD, including improvement of cognitive
function [188], anti-oxidative injury [188,189], anti-apoptosis
[188], inhibition of β-amyloid (Aβ) deposition and Aβ fibril
formation [190]. Ginkgo biloba-extract EGb 761 also exhibited
neuroprotective effects in several mouse models [191] as well as
maintaining and improving cognitive function in AD patients
[192,193]. In contrast, a double-blind placebo controlled study
found no effect on dementia in AD patients [194]. In vitro
studies indicate that the ginkgo extract activity is due to
inhibition of Aβ induced free radical generation and occurs in a
dose dependant manner [195].
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6 hepta-
diene-2,5 dione) (Fig. 8e), is the polyphenolic yellow pigmentunder oxidative conditions.
Fig. 7. Dityrosine formation under oxidative conditions.
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preservation [196]. Interestingly the prevalence of AD between
the ages of 70–79 years in India is 4.4-fold less than in the USA
[197]. The compound is neuroprotective against Aβ toxicity in
vitro [198] while also being anti-amyloidogenic [199,200].
Furthermore aged transgenic Tg2576 mice with high amyloid
plaque load either fed or injected with curcumin had less brain
amyloid load and plaque burden; and curcumin labelled plaques
[201]. Spectrophotometric studies indicate that curcumin is able
to bind the more readily redox reactive metals Cu and Fe but
does not bind Zn and therefore acts as an antioxidant by
chelating the redox active metal ions [202].
While the details of the mode of pathogenesis remains
elusive antioxidants that act to soak up the dangerous free
radicals probably have some protective value. However, since
they do not address the underlying cause of radical generation
(metal-induced redox chemistry) they may have limited value as
therapeutics once the disease has started to progress. This is
because the reactions that define oxidative stress are chain
reactions and once initiated give rise to a growing cascade ofFig. 8. The molecular structure of antioxidants that show potential as Alzheimer's dis
melatonin and (e) curcumin.events and therefore it is unlikely that sufficiently high
concentrations of drug can reach the active sites to effectively
soak up the radicals being generated. Therefore, antioxidants
may find their most beneficial role when used as prophylactics.
6.2. Metal coordinating compounds
An alternative approach is to target the initiating event in the
generation of free radicals: that is to employ metal complexing
agents to prevent the metal ions from participating in the redox
chemistry of Aβ that leads to the oxidative stress in AD. An
important property of a potential AD therapeutic is its ability to
cross the blood brain barrier (BBB). This excludes a large
number of common metal chelators as possibilities due to their
hydrophilic nature.
Desferrioxamine (N′-[5-(acetyl-hydroxy-amino)pentyl]-N-
[5-[3-(5-aminoopentyl-hydroxy-carbamoyl0propanoylamino]
pentyl]-N-hydroxy-butane diamide) (Fig. 9b), is a specific Fe
chelator with high affinity also for Cu, Zn and aluminium (Al)
[203,204]. In one trial desferrioxamine slowed the progressionease therapeutic treatments. (a) α-tocopherol, (b) ascorbic acid, (c) gossypin, (d)
Fig. 9. The molecular structure of metal binding compounds that show potential as Alzheimer's disease therapeutic treatments. (a) clioquinol, (b) desferrioxamine, (c)
bicyclam analogue JKL169, (d) triene and (e) tricyclodecan-9-yl-xanthogenate.
1984 D.G. Smith et al. / Biochimica et Biophysica Acta 1768 (2007) 1976–1990of AD. As a part of this study, the Al levels were monitored.
Although Al has received some interest due to high concentra-
tions being found in amyloid plaques and intracellular
neurofibrillary tangles of AD brain [205–208], no convincing
evidence has been published to suggest a role of the metal in the
development of the disease although it remains a controversial
issue [209]. Unfortunately no other metals were examined so it
is unclear as to whether the therapeutic effect of desferriox-
amine was actually due to chelation of other metals such as Cu
and Zn. Another drawback for desferrioxamine is that it is not
orally bioavailable.
Derivatives of a 14-membered saturated tetramine have
attracted some recent interest. Bicyclam analogue JKL169
(1,1′-xylyl bis-1,4,8,11 tetraaza cyclotetradecane) (Fig. 9c) was
effective in reducing Cu levels in brain cortex and is able to
maintain normal Cu levels in the blood, CSF and corpus
callossum in rats [210]. A number of other chelators have been
studied such as the lipophillic chelator DP109 that reduced the
level of aggregated insoluble Aβ and conversely increased
soluble forms [211]. The chelator triene (triethylenetetramine)
(Fig. 9d), which is used to treat Wilson's disease (intracellular
Cu accumulation disease) was ineffective in reducing cerebral
plaque concentration. This is attributed to the compound's
inability to cross the blood brain barrier [212]. Brain tissue pre-
exposed to tricyclodecan-9-yl-xanthogenate (Fig. 9e) showed
significant reduction in oxidative stress markers after exposure
to Aβ [213] however further work is required to evaluate
whether the compound has promise as potential therapeutic for
AD treatment.
Oral treatment with the chelator clioquinol (CQ, 5-chloro-7-
iodo-8-hydroxyquinoline) (a former antibiotic) (Fig. 9a) inTg2576 mice resulted in a reduction of cortical deposition of
amyloid (49%) with an improvement in general health and
weight parameters remaining stable compared to untreated mice
[212]. This quinoline compound is able to cross BBB and
actually increases the brain Cu and Zn levels in treated mice. The
increase in metal ions is suggested to be a result of CQ-metal
complexes forming in the intestinal tract and crossing the BBB
[210]. Clioquinol was used as an antibiotic, but was removed
from the market in 1971 as it was implicated in the development
of subacute myleo-optico-neuropathy (SMON) in some patients
in Japan. However the link between CQ administration and the
development of SMON in these patients is circumstantial as 25%
of the diagnosed patients did not receive CQ [214] andwas likely
due to a vitamin B-12 deficiency within that population
exacerbated by CQ [212,215]. The positive animal data lead to
CQ being trialled clinically to treated AD, the drug was
administered at much lower concentrations than was used to
treat bacterial infections [216]. CQ showed significant promise
for the treatment of AD, with a small phase II clinical trial
revealing positive effects of the drug administered orally in
moderately severe AD patients with no signs of SMON [216].
7. Conclusions
The brain requires high metal ion concentrations to carry out
its numerous functions. However the brain has a poor capacity
to cope with oxidative stress. Aberrant interactions between Aβ
and redox active metals could initiate a cascade of events
resulting in oxidative stress and chemically modified forms of
Aβ. These chemical modifications include the generation of
soluble covalently-linked oligomers of Aβ that have been
1985D.G. Smith et al. / Biochimica et Biophysica Acta 1768 (2007) 1976–1990linked to the toxicity of the peptide. A number of therapeutic
strategies aimed at ameliorating or inhibiting Aβ induced redox
chemistry, including the use of antioxidants and metal
complexing agents are currently being investigated for their
utility in treating AD. Therefore, defining the primary trigger
for the oxidative stress in AD and the role of Aβ in this process
should be critical to our understanding of AD pathogenesis.
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